食管癌放射治疗后程同期化疗的疗效分析

[目的]观察晚期不宜手术治疗食管癌病例放射治疗后程同期化疗的临床疗效及毒副作用。[方法]1997年6月至2000年3月，将130例不宜手术的晚期食管癌病例随机性分为后化组(66例)和单放组(64例)两个组，后化组于放疗的后程同期用2周期化疗(DF方案)，单放组作为对照。[结果]后化组1、3年生存率分别为65．2％、33．3％；单放组分别为46．9％、17．2％；后化组与单放组转移率分别为21．2％、37．5％，差异均有显著意义。后化组不良反应明显高于单放组。[结论]不宜手术的晚期食管癌病人放射治疗同期后程2周期化疗，较单纯放疗提高了1、3年生存率，毒副作用则有明显加重，但经治疗后病人可以耐受。

Simultaneous Chemo-radiotherapy for Esophageal Carcinoma in Late Course Radiotherapy

To assess the therapeutic benefit and the toxicity of chemo-radiotherapy for the patients with unresectable esophageal carcinoma.From1997June to2000March,130unresectable patients were random-ized into two groups:LCCR(late course chemo-radiotherapy)groups(66cases)and ACR(all course radiotherapy)group(64cases).The patients in LCCR group received two cycles of DDP and5-Fu regimen(DF)for three days in the late course.1-,3-year survival rates were65.2%,33.3%in LCCR group,46.9%,17.2%in ACR group respec-tively.Metastasize lymph nodes rate was21.2%in LCCR,37.5%in ACR group.Survival and node metastasis rates be-tween2groups were significantly different.The toxicity of LCCR group was obviously than that of ACR group.[Con-clusions]This method is able to improve the1-,3-year survival rate in unresectable esophageal carcinoma patients even though the toxicity increased obviously,but the patients is tolerable.